Needham Reiterates Buy on Apellis Pharmaceuticals, Maintains $85 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Joseph Stringer has reiterated a Buy rating on Apellis Pharmaceuticals (NASDAQ:APLS) and maintained a price target of $85.
September 20, 2024 | 4:41 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Joseph Stringer has reiterated a Buy rating on Apellis Pharmaceuticals and maintained a price target of $85, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a high price target by a reputable analyst suggests positive sentiment and potential upside for Apellis Pharmaceuticals. This could lead to increased investor interest and a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100